When can I safely administer vaccines after Cosentyx treatment?
The US Centers for Disease Control and Prevention (CDC) and the American Academy of Pediatrics (AAP) recommend a wait period before administering live-attenuated vaccines after biologic therapies, including Cosentyx, a tumor necrosis factor-alpha (TNF-alpha) inhibitor [1]. This is because biologics, including TNF-alpha inhibitors, can suppress the immune system, increasing the risk of vaccine-related complications, such as disseminated infection or vaccine failure.
Recommended waiting periods post-Cosentyx:
For live-attenuated vaccines, such as MMR, varicella, and rotavirus, the CDC recommends waiting at least 8 weeks or 2 months after the last dose of Cosentyx before administration [2].
For inactivated vaccines, such as flu, pneumococcal, and meningococcal conjugate vaccines, no specific waiting period is required, but the CDC recommends completing the vaccine series as soon as possible after completing biologic therapy [3].
Special considerations for certain vaccines:
Consult with the patient's healthcare provider or a specialist in infectious diseases to determine the best timing for vaccination, especially in the following cases:
- Live-attenuated vaccines in patients with autoimmune disease, including those on TNF-alpha inhibitors, should be given at a safe distance from the biologic therapy, typically 8 weeks or more after the last dose.
- Patients with certain chronic medical conditions, such as HIV, may require additional precautions or different vaccination schedules.
- Live-attenuated vaccines should be administered carefully in patients with weakened immune systems, as they may be at increased risk of severe vaccine-related complications.
Who to consult and next steps:
If you're considering vaccinating a patient who has completed Cosentyx treatment, consult the patient's healthcare provider or an immunologist to discuss the optimal timing and specific vaccination recommendations for that patient.
To ensure the patient's optimal health and minimize any potential risks, always adhere to the manufacturer's guidelines and seek guidance from a qualified healthcare professional.
References:
[1] Centers for Disease Control and Prevention. (2022). Use of live, attenuated intranasal influenza vaccine this season. Retrieved from https://www.cdc.gov/vaccines/hcp/index.html
[2] Centers for Disease Control and Prevention. (2022). General best practice guidelines for immunization. Retrieved from https://www.cdc.gov/vaccines/hcp/administering-guideline.html
[3] Centers for Disease Control and Prevention. (2022). Vaccines after biologics. Retrieved from https://www.cdc.gov/vaccines/hcp/patient-ed/faq/biologics-therapy.html
DrugPatentWatch.com can provide valuable information on the current patent status and expiration dates for Cosentyx and other biologic therapies [1].
Sources: